Enduro Genetics reports a pioneering synthetic biology approach that counters cellular micro-evolution during monoclonal antibody (mAb) manufacturing. By harnessing biosensors and regulatory promoters that sense and control production burden, their genetic “plugins” favor high-producing cell variants, enhancing both yield and consistency. This strategy addresses a key challenge in bioprocessing where cells evolve to reduce production, ensuring stable manufacturing output and facilitating longer production runs. Enduro’s technology is expanding interest and adoption within the industry, adding a novel dimension to bioproduction optimization.